Work

Effects of IONIS-HTTRx in Patients with Early Huntington’s Disease, Results of the First HTT-Lowering Drug Trial (CT.002)

Year: 2018

Type: article

Source: Neurology

DOI: 10.1212/wnl.90.15_supplement.ct.002

Authors: Sarah Tabrizi, Blair Leavitt, Holly Kordasiewicz, Christian Czech, Eric Swayze, Daniel A. Norris, Tiffany Baumann, Irene Gerlach, Scott Schobel, Anne Smith, Roger Lane, C. Frank Bennett

Institutions: University College London, University of British Columbia, Ionis Pharmaceuticals (United States), F. Hoffmann-La Roche AG

Language: English

Topic: Genetic Neurodegenerative Diseases

Subfield: Cellular and Molecular Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2802276893

FWCI: 2.163

Cites:

Cited by: 26

Related to: 10